Wedbush reiterates Outperform on Travere Therapeutics, $76 target
Wedbush reiterated an Outperform rating on Travere Therapeutics and set a $76.00 price target, implying 20.9% upside from the Sep 21 close of $62.86.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.